MetaVia Other Monday, November 16, 2026 +0.40 Positive

MevaVia preclinical data supports DA-1726 for liver disease and weight loss

MetaVia announced positive preclinical data showing its dual agonist DA-1726 increases FGF21 expression and promotes thermogenesis. The data suggests the compound may offer greater glucose lowering for liver-related diseases with potentially fewer side effects.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed